Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Hookipa Pharma Inc
Healthcare
P/NCAV
0.96x
Ticker
HOOK
Exchange
NASDAQ
Country
United States
Close
0.77 $
Mkt Cap
72.3M $
EV
-43.7M $
NCAV Burn Rate
4.6%
Current Ratio
3.5
Debt/Equity
0.01
EV/REV
-2.17x
EV/EBIT
0.4x
EV/FCF
0.8x
Dilution
24.5% p.A
Total Net Income
-338.2M $
Cheapness
93.0%
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average